Trial Name	Description
CE.9 CNS	Dr. Seth Climans LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS
CEC.6 CNS	Dr. S. Climans N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma.
NRG-BN003	Dr. Barbara Fisher Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma.
INDIGO CNS	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation
ACTION CNS	Dr. S. Climans The ACTION Study: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized Double-Blind, Placebo-Controlled, Multicenter Study
TMZ-Chrono CNS	Dr. Seth Climans A randomized, multicentre pilot trial evaluating the feasibility and efficacy of dosetiming (morning vs evening) of temozolomide in the treatment of glioblastoma.
CE.10 (VIGOR)	Dr. S. Climans Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)